Drug Trial Radar · NCT05970497
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Oct 31, 2023
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Krystal Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or for whom there is no standard of care therapy as well as the safety, tolerability, preliminary efficacy, and immunologic effect of KB707 administered in combination with Opdualag to subjects with unresectable or metastatic melanoma. Subjects in dose escalation (Cohorts 1 through 3) and dose expansion (Cohort 4) will receive intratumoral injections of KB707 approximately every three weeks. Cohorts 1 through 4 are closed to new enrollment. Dose expansion Cohort 5 and Cohort 6 will evaluate subjects with advanced melanoma. Subjects in Cohort 5 will receive intratumoral injections of KB707 biweekly (q2w), delivered in combination with Opdualag (dosed every q4w per prescribing information). Subjects in Cohort 6 will receive intratumoral injections of KB707 biweekly (q2w), delivered in combination with Keytruda (dosed every q6w per prescribing information). All subjects will be treated until disease progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.
Conditions
- Cancer
- Melanoma Stage III
- Melanoma Stage IV
- Cutaneous Melanoma
Interventions
KB707Biological
Genetically modified herpes simplex type 1 virus
OpdualagDrug
Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors)
KEYTRUDA ®( Pembrolizumab)Drug
Immunotherapy (PD-1 immune checkpoint inhibitor)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of adverse events (AEs)Time frame: up to 36 months
- Percentage of serious adverse events (SAEs)Time frame: up to 36 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
UCLA Health
Los Angeles, California · Recruiting
Mission Dermatology Center
Rancho Santa Margarita, California · Recruiting
BRCR Global
Weston, Florida · Recruiting
IU Simon Comprehensive Cancer Center
Indianapolis, Indiana · Recruiting
Henry Ford Cancer Institute
Detroit, Michigan · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Morristown Medical Center / Atlantic Health System
Morristown, New Jersey · Recruiting
Weill Cornell Medicine-New York-Presbyterian Hospital
New York, New York · Recruiting
Gabrail Cancer Center Research
Canton, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Renovatio Clinical - El Paso
El Paso, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Renovatio Clinical - The Woodlands
The Woodlands, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.